Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

“…Eradicating hepatitis C infection results in numerous health benefits, including reduced rates of all‐cause mortality, cirrhosis, hepatic decompensation, and HCC . Successful treatment also confers improvement in extrahepatic manifestations of HCV disease, including cryoglobulinemic vasculitis and HCV‐related non‐Hodgkin lymphoma and other lymphoproliferative disorders, as well as improved productivity and quality of life . Given these and other benefits associated with virologic cure, the HCV guidance panel strongly recommends antiviral treatment for all adults with acute or chronic HCV infection (except those with a short life expectancy that cannot be remediated).…”

Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences

“…In summary, the current data suggest that significant PRO gains occur with the new DAA treatment regimens regardless of the patient population (coinfected, advanced fibrosis, retreatments, and treatment failures) with the largest gains noted in those patients who obtain SVR [84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102]. Therefore, regardless of the treatment needed, SVR should be the goal, not only to improve clinical outcomes, but also to improve patients' experience as documented by improving PRO scores.…”

“…In contrast, the use of the new interferon-and ribavirin-free all oral regimens for HCV treatment have resulted in significant improvement in patients' HRQOL scores as early as 2 weeks into the treatment, especially in those domains most affected by the hepatitis C virus [physical functioning, work productivity (presenteeism), social functioning, activity]. In fact, by the end of treatment with the DAA's many of the significantly improved scores closely approximated or surpassed the HRQOL scores of the general population without HCV [84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101]. These PRO gains have also been observed in patients with both early and advanced fibrosis [90,98].…”

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)

“…Furthermore, in comparison with the baseline levels, although MCP-1 levels decreased in RBV+ arm and increased in RBV− group, a change in MCP-1 level significantly and positively correlated with MH scores at EOT. However, it is not solely mental health that is affected with MCP-1 levels, as in a very recent study, Gerber et al [55] showed that MCP-1 levels were associated with persistent fatigue after SVR-12 among HCV patients treated with LDV/SOF.…”